Replies to post #170017 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Well DZP was, as per the CTAD 18 presentation, part of KEM analysis without being flagged as significant.

We just don't know if it was because only 1 patient was still on DZP at 148 weeks perhaps in the low concentration cohort or that DZP presents little competition to A2-73 because of its allosteric modulation of not just S1R.

But, yes I guess you could ask Anavex if you really want to know.